Manufacturer
PFIZER (PERTH) PTY. LTD.
Contents
Methotrexate
Indication
Choriocarcinoma, Mycosis fungoides, Acute lymphoblastic leukaemia, Crohn's disease, Meningeal leukaemia, Osteosarcoma, Breast cancer, Advanced lymphosarcoma, Acute lymphoblastic leukaemia
Instruction
Administer via IM, IV and Intrathecal.
Drug interaction
Decreased effectiveness with folic acid and its derivatives.
Potentially Fatal: Increased toxicity with NSAIDs and salicylates; probenecid; some penicillins; aminoglycosides neomycin and paromomycin; sulfonamides such as sulfafurazole and sulfamethoxazole; co-trimoxazole or trimethoprim; nephrotoxic agents (e.g. cisplatin); ciclosporin; etretinate. Synergistic enhancement of effects with fluorouracil. Increased bioavailability of mercaptopurine. Reduces serum-valproate concentrations. Reduced serum concentrations with colestyramine. Increased serum concentrations with omeprazole.
Malaysia
